--Cleveland BioLabs is back in the race to develop an anti-radiation drug for the U.S. military. and I couldn't be happier. I know who we need on this name biobottom I was bad and didn't return an email I wonder if he's still out there...... Osiris nabbed the coveted contract and investors fled CBLI. But Cleveland BioLabs got back into the game last week when it won a developmental contract worth up to $8.9 million from the Defense Department to develop its Protectan drug as a way of treating soldiers who have been exposed to radiation. While the contract doesn't commit the government to buying any Protectan, it gives Cleveland BioLabs valuable funding to continue its research on the drug, which is in the testing stage and still needs to be approved for use in humans. What's big here is the " stockpiling angle " whatever drug is bought will be bought massively by governments and then of course they dwindle in potency over time... can you say REORDER! This is going to be a really great contract when it comes....
"I think we're in a good position to win." the CEO says! With Cleveland BioLabs' Protectan costing around $200 a dose, 1 million orders would mean roughly $200 million in sales. That would turn Cleveland BioLabs from a fledgling research company to a full-blown drug manufacturer in a hurry.
Even better, from Cleveland BioLabs' perspective, is that the stockpiled doses eventually lose their effectiveness, which means ongoing sales to keep the supplies fresh. If the military market fully develops, if Homeland Security starts stockpiling doses for civilians, if Israel does the same, CEO Fonstein thinks Cleveland Bio- Labs could be looking at a market worth $500 million a year. >If Protectan works and if the drug wins approval for use from regulators.
Fonstein is encouraged by recent test results, which showed that Protectan helped monkeys survive two-thirds of the time after they were exposed to lethal levels of radiation and were given the drug 48 hours after exposure. That was much better than the 25 percent survival rate among a control group.
Those results, released publicly last week, weren't available when Cleveland BioLabs originally applied for the contract that ended up going to Osiris, whose drug has the disadvantage of costing about $10,000 a dose and can only be administered in clinical settings!!! hello $10 grand a pop! no wonder the gov is looking to CBLI, maybe we all should to.... Protectan can be administered by fellow soldiers on the battlefield.
Cleveland BioLabs hopes to have Protectan ready for military use in less than three years, mainly because the approval standards for military use aren't as stringent as the ones used for medical use. That's a big investor heads up we don't need FDA approval for good pub here just ARMY purchases!
Full-blown FDA approval will require additional testing beyond that required by the military. Of course there are other medical targets for the drug, but that seems a long ways off. For now, we have a cheaper product by a lot that new studdies have shown has some good numbers in mice. BRING ON THE HUMANS!
Keep an eye on CBLI. ~stoney
"I think we're in a good position to win." the CEO says! With Cleveland BioLabs' Protectan costing around $200 a dose, 1 million orders would mean roughly $200 million in sales. That would turn Cleveland BioLabs from a fledgling research company to a full-blown drug manufacturer in a hurry.
Even better, from Cleveland BioLabs' perspective, is that the stockpiled doses eventually lose their effectiveness, which means ongoing sales to keep the supplies fresh. If the military market fully develops, if Homeland Security starts stockpiling doses for civilians, if Israel does the same, CEO Fonstein thinks Cleveland Bio- Labs could be looking at a market worth $500 million a year. >If Protectan works and if the drug wins approval for use from regulators.
Fonstein is encouraged by recent test results, which showed that Protectan helped monkeys survive two-thirds of the time after they were exposed to lethal levels of radiation and were given the drug 48 hours after exposure. That was much better than the 25 percent survival rate among a control group.
Those results, released publicly last week, weren't available when Cleveland BioLabs originally applied for the contract that ended up going to Osiris, whose drug has the disadvantage of costing about $10,000 a dose and can only be administered in clinical settings!!! hello $10 grand a pop! no wonder the gov is looking to CBLI, maybe we all should to.... Protectan can be administered by fellow soldiers on the battlefield.
Cleveland BioLabs hopes to have Protectan ready for military use in less than three years, mainly because the approval standards for military use aren't as stringent as the ones used for medical use. That's a big investor heads up we don't need FDA approval for good pub here just ARMY purchases!
Full-blown FDA approval will require additional testing beyond that required by the military. Of course there are other medical targets for the drug, but that seems a long ways off. For now, we have a cheaper product by a lot that new studdies have shown has some good numbers in mice. BRING ON THE HUMANS!
Keep an eye on CBLI. ~stoney